If you have been reading about clinical evidence and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-01-25. Numbers and descriptions here follow the published literature rather than marketing material.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
| Property | Value | Notes |
|---|---|---|
| Molar mass | Approximately 1419.5 g/mol | Calculated from the reported 15-residue sequence |
| Molecular formula | C62H98N16O22 | Based on the same sequence |
| Appearance | White to off-white powder | Typical of a lyophilized preparation |
| Solubility class | Freely soluble in water | Also dissolves in saline solutions |
| Typical storage temperature | Minus 20 degrees Celsius, dry | Refrigeration advised after reconstitution |
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
=== Approved drugs === Escitalopram (Cipralex; Entact; Lexapro; LU-26054; MLD-55; (S)-citalopram; Seroplex; Sipralex; Sipralexa) – selective serotonin reuptake inhibitor (SSRI) [14] Fluoxetine (LY-110140; Prozac; Reneuron; Sarafem) – selective serotonin reuptake inhibitor (SSRI) [15] Fluoxetine (Fluoxetine Tablets) – selective serotonin reuptake inhibitor (SSRI) [16] Paroxetine (Aropax; BRL-29060; Deroxat; Divarius; FG-7051; Frosinor; Motivan; NNC-207051; Paxil; Seroxat; SI-211103; Tagonis) – selective serotonin reuptake inhibitor (SSRI) [17] Paroxetine (Dropax; Dropaxin; Serestill) – selective serotonin reuptake inhibitor (SSRI) [18] Sertraline (Aremis; Besitran; CP-51974; Gladem; Lustral; Serad; Serlain; Tatig; Zoloft) – selective serotonin reuptake inhibitor (SSRI) [19] Venlafaxine (Dobupal; Efexor XR; Effexor; Effexor XR; Elafax; WY-45030; WY-45651; WY-45655) – serotonin–norepinephrine reuptake inhibitor (SNRI) [20]
=== Lymphangioleiomyomatosis === In May 2015, the FDA approved sirolimus to treat lymphangioleiomyomatosis (LAM), a rare, progressive lung disease that primarily affects women of childbearing age. This made sirolimus the first drug approved to treat this disease. LAM involves lung tissue infiltration with smooth muscle-like cells with mutations of the tuberous sclerosis complex gene (TSC2). Loss of TSC2 gene function activates the mTOR signaling pathway, resulting in the release of lymphangiogenic growth factors. Sirolimus blocks this pathway. The safety and efficacy of sirolimus treatment of LAM were investigated in clinical trials that compared sirolimus treatment with a placebo group in 89 patients for 12 months. The patients were observed for 12 months after the treatment had ended. The most commonly reported side effects of sirolimus treatment of LAM were mouth and lip ulcers, diarrhea, abdominal pain, nausea, sore throat, acne, chest pain, leg swelling, upper respiratory tract infection, headache, dizziness, muscle pain and elevated cholesterol. Serious side effects including hypersensitivity and swelling (edema) have been observed in renal transplant patients. While sirolimus was considered for treatment of LAM, it received orphan drug designation status because LAM is a rare condition. The safety of LAM treatment by sirolimus in people younger than 18 years old has not been tested.
=== Subcellular membrane fluidity under cold and osmotic stress === The efficiency of lactic acid bacteria cryopreservation is not consistent and may lead to cell death. Lactobacillus delbrueckii subsp. bulgaricus has adapted to defend against cold stress. The way most cells react to the cold is by changing the fluidity of the cellular membrane, but this particular bacterium has acquired different tactics to fight against cold stress. The first way to cope with the cold is to increase viscosity by taking in compounds such as disaccharides, polysaccharides, amino acids and antioxidants. The second strategy used is performed by inducing active responses during the fermentation or post-fermentation processes. By modifying these it will change the temperature, pH and medium composition. This results in specific metabolic pathways becoming active, with the synthesis of cold shock proteins.
The concept of border controls has its origins in antiquity. In Asia, the existence of border controls is evidenced in classical texts. The Arthashastra (c. 3rd century BCE) makes mention of passes issued at the rate of one masha per pass to enter and exit the country. Chapter 34 of the Second Book of Arthashastra is concerned with the duties of the Mudrādhyakṣa (lit. 'Superintendent of Seals') who must issue sealed passes before a person could enter or leave the countryside. Passports resembling those issued today were an important part of the Chinese bureaucracy as early as the Western Han (202 BCE-220 CE), if not in the Qin dynasty. They required details such as age, height, and physical features. The passports (zhuan) determined a person's ability to move throughout imperial counties and through points of control. Even children needed passports, but those of one year or less who were in their mother's care may not have needed them.
nucleosome-depleted region (NDR) A region of a genome or chromosome in which long segments of DNA are bound by few or no nucleosomes, and thus exposed to manipulation by other proteins and molecules, especially implying that the region is transcriptionally active.
Sources: en.wikipedia.org
Australians voted The Lord of the Rings "My Favourite Book" in a 2004 survey conducted by the Australian ABC. In a 1999 poll of Amazon.com customers, The Lord of the Rings was judged to be their favourite "book of the millennium". In 2002 Tolkien was voted the 92nd "greatest Briton" in a poll conducted by the BBC, and in 2004 he was voted 35th in the SABC3's Great South Africans, the only person to appear in both lists. His popularity is not limited to the English-speaking world: in a 2004 poll inspired by the UK's "Big Read" survey, about 250,000 Germans found The Lord of the Rings to be their favourite work of literature.
== Pollepel Island chevaux-de-frise (1776–1777) == Another cheval-de-frise was undertaken across the Hudson between Plum Point on the east bank and Pollepel Island north of West Point. The defenses were never fully completed, and its importance was overshadowed by completion of the Great Chain at West Point the following year.
In nuclear engineering, a delayed neutron is a neutron released not immediately during a nuclear fission event, but shortly afterward—ranging from milliseconds to several minutes later. These neutrons are emitted by excited daughter nuclei of certain beta-decaying fission products. In contrast, prompt neutrons are emitted almost instantaneously—within about 10−14 seconds—at the moment of fission. During fission, a heavy nucleus splits into two smaller, neutron-rich fragments (fission products), releasing several free neutrons known as prompt neutrons. Many of these fission products are radioactive and typically undergo beta decay to reach more stable configurations. In a small subset of cases, the beta decay of a fission product results in a daughter nucleus in an excited state with enough energy to emit a neutron. This neutron, emitted shortly after fission but delayed due to the beta decay process, is called a delayed neutron. The delay in neutron emission arises from the time required for the precursor nuclide (the beta-decaying fission product) to undergo beta decay—a process that takes orders of magnitude longer than the prompt emission of neutrons during fission. While the delayed neutron is emitted almost immediately after beta decay, it is actually released by the excited daughter nucleus produced in that decay. Therefore, the overall timing of delayed neutron emission is governed by the beta decay half-life of the precursor. Delayed neutrons are critically important for controlling nuclear reactors.
Sunak reshuffles his shadow cabinet, with Andrew Mitchell replacing David Cameron as Shadow Foreign Secretary after the latter resigns. Richard Fuller replaces Richard Holden as Conservative Party Chairman after Holden resigns from the role. 9 July – Starmer meets England's 12 regional mayors to discuss "a major programme of devolution" of powers from Westminster to local government. The first meeting of the new 2024 Parliament of the United Kingdom takes place. The Ministry of Housing, Communities and Levelling Up reverts to its pre-Johnson era name of the Ministry of Housing, Communities and Local Government. New Health Secretary Wes Streeting begins talks with junior doctors in England aimed at ending their pay dispute. Starmer makes the unusual move of appointing five newly elected MPs to government posts: Georgia Gould is appointed as a parliamentary secretary in the Cabinet Office, Miatta Fahnbulleh is appointed as a junior minister in the Department for Energy Security and Net Zero, Alistair Carns is appointed as Minister of State for Veterans' Affairs, Sarah Sackman is appointed as Solicitor General, and Kirsty McNeill is appointed as a junior minister in the Scotland Office. In an open letter to SNP members following the party's defeat in Scotland, former deputy leader Jim Sillars has described John Swinney's leadership as "a busted flush" and Nicola Sturgeon as "Stalin's wee sister". 10 July – Starmer travels to Washington, D.C., his first foreign trip as UK prime minister, to attend the 75th NATO summit.
Sources: en.wikipedia.org
1900 marked the so-called rediscovery of Mendel by Carl Correns, who arrived at Mendel's laws (which were not actually present in Mendel's work). Soon after, cytologists (cell biologists) proposed that chromosomes were the hereditary material. This was taken up by Carl Correns and others between 1910 and 1915 as the "Mendelian-chromosome theory" of heredity. Thomas Hunt Morgan and the "Drosophilists" in his fly lab applied this to a new model organism. They hypothesized crossing over to explain linkage and constructed genetic maps of the fruit fly Drosophila melanogaster, which became a widely used model organism. Hugo de Vries tried to link the new genetics with evolution; building on his work with heredity and hybridization, he proposed a theory of mutationism, which was widely accepted in the early 20th century. Lamarckism, or the theory of inheritance of acquired characteristics also had many adherents. Darwinism was seen as incompatible with the continuously variable traits studied by biometricians, which seemed only partially heritable. In the 1920s and 1930s—following the acceptance of the Mendelian-chromosome theory— the emergence of the discipline of population genetics, with the work of R.A. Fisher, J.B.S. Haldane and Sewall Wright, unified the idea of evolution by natural selection with Mendelian genetics, producing the modern synthesis. The inheritance of acquired characters was rejected, while mutationism gave way as genetic theories matured.
oxidative phosphorylation during aerobic respiration in the mitochondrion from adenosine diphosphate (ADP). substrate-level phosphorylation during glycolysis and the Krebs cycle. By photophosphorylation in the chloroplasts of plant cells.
By 1830, the German mathematician Carl Friedrich Gauss had determined the boundary conditions governing capillary action (i.e., the conditions at the liquid-solid interface). In 1871, the British physicist Sir William Thomson (later Lord Kelvin) determined the effect of the meniscus on a liquid's vapor pressure—a relation known as the Kelvin equation. German physicist Franz Ernst Neumann (1798–1895) subsequently determined the interaction between two immiscible liquids. Albert Einstein's first paper, which was submitted to Annalen der Physik in 1900, was on capillarity.
Sources: en.wikipedia.org
It does not occur in the form that is supplied commercially. Its sequence matches a fragment of a larger gastric protein, and the research material is produced synthetically in a laboratory. The fragment described in the early literature is generally the same synthetic pentadecapeptide.
It marks the position of the sequence inside the original protein. The label traces back to early work fractionating gastric juice and describing a body protection compound. The figure does not refer to molecular weight or to the count of amino acids.
No. The sequence has no cysteine residues, so disulfide bridges cannot form. That feature makes it easier to handle than many small proteins that depend on multiple cysteines for structure.
Human data are limited. Most evidence comes from animal experiments and from small or uncontrolled reports. The absence of large trials means clinical effects and safety are not firmly established.